The phase 3 MIRASOL trial confirms improved progression-free and overall survival with mirvetuximab soravtansine over chemotherapy. The drug's benefits outweigh the impact of TEOEs, reinforcing ...
How do the primary analysis results of the MIRASOL trial differ from the primary analysis results? Were there any unexpected findings? Back then, when we did the primary analysis, we had a follow ...
TipRanks on MSN16d
AbbVie announces final analysis of Phase 3 MIRASOL trialAbbVie (ABBV) announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ...
Elahere showed superior efficacy over chemotherapy in progression-free survival, objective response rate, and overall survival in the MIRASOL trial. The treatment reduced the risk of tumor progression ...
US-based pharmaceutical company AbbVie has reported the final analysis from the Phase III MIRASOL trial, which assessed its antibody-drug conjugate (ADC) Elahere against chemotherapy for treating ...
Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα ...
(RTTNews) - AbbVie (ABBV) announced that final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE or mirvetuximab ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback